SHIFT Newsroom · GLOBAL
Reflux reports and GLP-1 medicines: pharmacovigilance findings
A study in Gut and Liver examined reflux reporting signals in adverse-event databases from the US, Japan and Canada.
A study in Gut and Liver examined reflux reporting signals in adverse-event databases from the US, Japan and Canada. Disproportionate reporting can identify a question for further investigation, but it does not measure how often reflux occurs among all users or prove that a medicine caused it. This study is not a source for UK licensing or NHS commissioning decisions.
SHIFT’s take
Read the study design and limits alongside the finding. This article does not determine individual treatment suitability.